Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Non-Current Debt: 2017-2018

Historic Non-Current Debt for Cidara Therapeutics (CDTX) over the last 2 years, with Sep 2018 value amounting to $9.3 million.

  • Cidara Therapeutics' Non-Current Debt rose 13.05% to $9.3 million in Q3 2018 from the same period last year, while for Sep 2018 it was $9.3 million, marking a year-over-year increase of 13.05%. This contributed to the annual value of $7.2 million for FY2017, which is N/A change from last year.
  • According to the latest figures from Q3 2018, Cidara Therapeutics' Non-Current Debt is $9.3 million, which was down 6.63% from $9.9 million recorded in Q2 2018.
  • In the past 5 years, Cidara Therapeutics' Non-Current Debt registered a high of $9.9 million during Q2 2018, and its lowest value of $7.2 million during Q4 2017.
  • In the last 2 years, Cidara Therapeutics' Non-Current Debt had a median value of $9.2 million in 2017 and averaged $8.8 million.
  • Examining YoY changes over the last 5 years, Cidara Therapeutics' Non-Current Debt showed a top increase of 13.05% in 2018 and a maximum decrease of 20.42% in 2018.
  • Over the past 2 years, Cidara Therapeutics' Non-Current Debt (Quarterly) stood at $7.2 million in 2017, then climbed by 13.05% to $9.3 million in 2018.
  • Its last three reported values are $9.3 million in Q3 2018, $9.9 million for Q2 2018, and $7.8 million during Q1 2018.